Mast Therapeutics (NASDAQ:SVRA) was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report issued on Tuesday, January 9th.
A number of other brokerages also recently issued reports on SVRA. JMP Securities started coverage on Mast Therapeutics in a report on Monday, September 11th. They set an “outperform” rating and a $20.00 price target on the stock. Roth Capital reduced their price target on Mast Therapeutics from $40.00 to $32.00 and set a “buy” rating on the stock in a report on Tuesday, October 31st. Canaccord Genuity boosted their price target on Mast Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a report on Monday, October 30th. ValuEngine downgraded Mast Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Finally, Zacks Investment Research downgraded Mast Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, November 23rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. Mast Therapeutics has an average rating of “Buy” and an average price target of $23.58.
Shares of Mast Therapeutics (NASDAQ SVRA) opened at $13.05 on Tuesday. Mast Therapeutics has a 52 week low of $4.60 and a 52 week high of $17.19. The company has a debt-to-equity ratio of 0.20, a quick ratio of 9.15 and a current ratio of 9.15. The stock has a market capitalization of $398.03, a PE ratio of -3.12 and a beta of 0.18.
In related news, Director Yuri Pikover purchased 50,000 shares of the business’s stock in a transaction that occurred on Friday, October 27th. The shares were bought at an average price of $7.85 per share, for a total transaction of $392,500.00. Following the purchase, the director now directly owns 150,000 shares of the company’s stock, valued at approximately $1,177,500. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 6.93% of the company’s stock.
Mast Therapeutics Company Profile
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Receive News & Ratings for Mast Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics and related companies with our FREE daily email newsletter.